BiYonDeuMeDiSeun lands Yonsei follow-on for jaw-disorder therapeutic
What's the deal? Digital health startup BiYonDeuMeDiSeunDealroom has a profile for this one. Try Dealroom → raised a follow-on investment from Yonsei University in October, the company said. The amount was not disclosed by mutual agreement.
What does it do? Founded by dentists, the company developed Clickless, a software medical device for patients with temporomandibular disorder (TMD). The program bundles cognitive behavioural therapy, exercise, meditation, and patient education so users can manage symptoms outside the clinic.
Why now? The company secured approval from South Korea's Ministry of Food and Drug Safety in December, validating Clickless through a multi-centre confirmatory trial. The new funding will go toward wider domestic commercialisation, stronger clinical evidence, and overseas expansion.
What's the endgame? BiYonDeuMeDiSeun is targeting the US, China, Japan, Singapore, and Europe, pursuing joint research, local device approvals, and distribution networks. It also plans to extend its software-based treatments to other conditions beyond TMD.
The deal marks the fourth company Yonsei University has backed directly. "I am deeply grateful to receive follow-on investment from my alma mater," chief executive officer Kim Dae-hyun said, adding the company aims to establish the device "as a new treatment option in the global medical market." (translated from Korean)
What could go wrong? Approval is only the first hurdle. South Korean digital therapeutics still face limited insurance reimbursement and patient access, so turning the funding into real prescriptions and overseas traction remains unproven.
The signal: With the amount undisclosed, the story is less about size than about an existing backer doubling down at the commercialisation stage. As digital therapeutics move from trials into clinics, the real test is no longer regulatory clearance but prescription volume and clinical evidence — and whether a university-born startup can build the business case to match.
Read more: venturesquare.net
Image credit: Generated with Gemini
